Company Overview and News
You can stream/download the full conversation, including the podcast extras on iTunes, Bloomberg, Overcast, and Soundcloud. Our earlier podcasts can all be found on iTunes, Soundcloud, Overcast and Bloomberg.
TOKYO — Thirty percent of prefectures, ordinance-designated cities and prefectural capitals are using or plan to use from this fiscal year or later social media to counsel young people and others who are contemplating suicide, a Yomiuri Shimbun survey has found.
The company is hovering around its 52-week low with a 7.05 EV/EBITDA, after a year that saw 20% YoY revenue growth.
Japanese telecom giant SoftBank on Wednesday reported a surge in its annual operating profit, driven by the increasing value of its Vision Fund and robust performances from its telecoms units.
SoftBank Group Corp. named Marcelo Claure chief operating officer, elevating Sprint Corp.’s top executive into a broader role after he negotiated a merger between the U.S. wireless operator and T-Mobile U.S. Inc.
The Nikkei 225 average rose, although slightly, Tuesday, buoyed by the yen’s weakness against the dollar and strong earnings at Japanese companies.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The following slide deck was published by Yahoo Japan Corp. ADR in conjunction with their 2017 Q4 earnings call.
The quarter was characterized by EPS, margin, and revenue expansion. And, it will continue throughout the year.
Advanced Micro Devices, Inc. (AMD - Free Report) reported non-GAAP earnings of 11 cents per share for first-quarter 2018 compared with break-even reported in the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate of 9 cents per share. Revenues increased 40% year over year to $1.65 billion and exceeded the Zacks Consensus Estimate of $1.52 billion. The accelerated adoption of the company’s products in the PC, gaming and data center industries primarily led to its impressive performance.
Tokyo is vying to become an innovation hub for entrepreneurs and investors, challenging Japan’s reputation as an environment that fails to nurture entrepreneurship, and a new nonprofit organization is hoping to play a leading role.
April 13 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Friday:
With the Financial Services Agency implementing greater oversight in the wake of the ¥58 billion Coincheck heist, many young and small cryptocurrency exchanges are finding it difficult to conduct business and looking to call it quits.
Rakuten Inc. got the green light Friday from a government panel to become the nation’s fourth major wireless carrier, granting the e-commerce giant access to a fierce competition for subscribers alongside industry heavyweights who have long dominated the cellular market.
SANTA CLARA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- AMD (NASDAQ:AMD) today announced that Yahoo Japan Corporation will be the first internet service provider in Japan to benefit from the deployment of AMD EPYC™ 7000 series processors. The internet-search giant’s evaluation and deployment of AMD EPYC™ 7551P processors adds a notable customer to the ever-expanding list of global businesses committed to elevating the performance and efficiency of their server resources with AMD.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET